Yuehua Zhou

Yuehua Zhou

Auto-generated profile, based on publicly available information

Yuehua Zhou

Top Alliance Biosciences Inc., Suzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Cancer Immunology Research
Verified
Journal Article
Open access
SWSheng Wang
Sheng Wang
DXDuo Xu
Duo Xu
YWYuan Wang
Yuan Wang
YZYuehua Zhou
Yuehua Zhou
LXLingyan Xiao
Lingyan Xiao
BLBo Liu
Bo Liu
Radio-immunotherapy has antitumor activity but also causes toxicity, which limits its clinical application. JS-201 is a dual antibody targeting PD-1 and TGF-β signaling. We investigated the antitumor effect of JS-201 combined with radiotherapy (RT) and the effect on radiation-induced lung injury (RILI). Different tumor models were established to detect the antitumor effects of the combination of JS-201 and RT, and RILI models were established to observe the effects of JS-201. Transcriptome sequencing showed that JS-201 optimized the tumor microenvironment by inhibiting extracellular matrix formation and angiogenesis. Combining JS-201 with RT further increased the inflammatory response and immune infiltration and showed great abscopal effects in Lewis lung cancer luciferase-positive models. Single-cell sequencing demonstrated that JS-201 reduced fibroblast proliferation by inhibiting the TGF-β/Smad pathway and the release of neutrophil extracellular traps mediated by ROS, thereby relieving radiation-induced pulmonary fibrosis. In conclusion, the JS-201 and RT combination enhances antitumor effects while mitigating acute and chronic RILI, and it may have potential for translational investigation as a cancer treatment strategy.

17 June 2026
Verified
Other
Open access
PDF file
SWSheng Wang
Sheng Wang
DXDuo Xu
Duo Xu
YWYuan Wang
Yuan Wang
YZYuehua Zhou
Yuehua Zhou
LXLingyan Xiao
Lingyan Xiao
BLBo Liu
Bo Liu
Figure S3. The supplement to IHC and RNA-seq results of LLC tumor tissues.

2 May 2025
Verified
Other
Open access
PDF file
SWSheng Wang
Sheng Wang
DXDuo Xu
Duo Xu
YWYuan Wang
Yuan Wang
YZYuehua Zhou
Yuehua Zhou
LXLingyan Xiao
Lingyan Xiao
BLBo Liu
Bo Liu
Figure S6. The supplement to RNA-seq and analysis of mice lungs 1 month after radiotherapy.

2 May 2025
Verified
Other
Open access
PDF file
SWSheng Wang
Sheng Wang
DXDuo Xu
Duo Xu
YWYuan Wang
Yuan Wang
YZYuehua Zhou
Yuehua Zhou
LXLingyan Xiao
Lingyan Xiao
BLBo Liu
Bo Liu
Figure S3. The supplement to IHC and RNA-seq results of LLC tumor tissues.


17 June 2026
Verified
Other
Open access
PDF file
SWSheng Wang
Sheng Wang
DXDuo Xu
Duo Xu
YWYuan Wang
Yuan Wang
YZYuehua Zhou
Yuehua Zhou
LXLingyan Xiao
Lingyan Xiao
BLBo Liu
Bo Liu
Figure S8. In vivo biosafety evaluation of JS-201 and summary of combination therapy.